Link

PDFs and Translations

This page is a collection of publications that (1) are either not available online or are not readily accessible online and have been uploaded (PDFs Only section); (2) are not in English and have been translated (Translations Only section); or (3) both of the preceding (PDFs and Translations section).

PDFs Only

Not Previously Available Online

  • Agarwal, V. R., Sasano, H., Takayama, K., Rosenthal, I. M., Walton, R., Simpson, E. R., & Bulun, S. E. (1997). Excessive Levels of Aromatase P450 and its Transcripts in Breast Adipose Tissue of a Girl with Pubertal Macromastia [Abstract P1-393]. In The Endocrine Society - Annual Meeting, Program and Abstracts: 79th Meeting, June 11-14, 1997, Minneapolis, Minnesota. / Proceedings of the 79th Annual Meeting of the Endocrine Society; 1997 June 11-14; Minneapolis, MN, USA. Bethesda, Maryland: Endocrine Society Press. [Google Books] [WorldCat] [PDF]
  • Anderson, W. A. (1962). Experimental stimulation of breast development in the teen-age female. The Journal of the Medical Society of New Jersey, 59, 541–543. [Google Scholar] [PubMed] [PDF]
  • Asscheman, H., Gooren, L. J. G., & Megens, J. (1989). Physical Changes During Hormonal Treatment in Male-to-Female Transsexuals. In Billowitz, A. (Ed.). Proceedings of the XIth Harry Benjamin International Gender Dysphoria Association Symposium, Cleveland, Ohio, September 20–23, 1989 (pp. 14–15). Palo Alto, California: Harry Benjamin International Gender Dysphoria Association. [Google Scholar] [PDF]
  • Chakmakjian, Z. H., & Zachariah, N. Y. (1987). Bioavailability of progesterone with different modes of administration. The Journal of Reproductive Medicine, 32(6), 443–448. [Google Scholar] [PubMed] [PDF]
  • Hamburger, C., & Benjamin, H. (1969). Endocrine Treatment of Male and Female Transsexualism / Appendix for the Practicing Physician: Suggestions and Guidelines for the Management of Transsexuals. In Green, R., & Money, J. (Eds.). Transsexualism and Sex Reassignment (pp. 291–307). Baltimore: John Hopkins University Press. [Google Scholar] [Google Books] [PDF]
  • Ibrahim, S. (1996/1998). Pharmakokinetische Untersuchungen mit Östradiolvalerat und Hydroxyprogesteroncaproat in Depotform nach einmaliger Applikation bei 24 postmenopausalen Frauen. [Pharmacokinetic studies with estradiol valerate and hydroxyprogesterone caproate in depot form after a single application in 24 postmenopausal women.] (Doctoral dissertation, Dresden University of Technology.) [Google Scholar] [WorldCat] [Partial PDF]
  • Jacobsohn, D. (1961). Hormonal Regulation of Mammary Gland Growth. In Kon, S. K., & Cowie, A. T. (Eds.). Milk: The Mammary Gland and Its Secretion, Volume 1 (pp. 127–160). New York: Academic Press. [Google Scholar] [PDF]
  • Kohli, M., & McClellan, J. (2001). Parenteral Estrogen Therapy in Advanced Prostate Cancer: Retrospective Analysis of Intra-Muscular Estradiol Valerate in “Hormone Refractory” Prostate Disease. In Grunberg, S. M. (Ed.). Proceedings of the American Society of Clinical Oncology [Proc Am Soc Clin Oncol / Proceedings of ASCO], 20 [Thirty-Seventh Annual Meeting of the American Society of Clinical Oncology, May 12–15, 2001, San Francisco, California], 164b–164b (abstract no. 2407). Baltimore: Lippincott Williams & Wilkins. [ISSN:1081-0641] [ISBN-10:0-9664495-3-3] [Google Scholar] [OCLC:107121093] [OCLC:107121085] [OCLC:1132117477] [PDF]
  • Kohli, M., Alikhan, M. A., Spencer, H. J., & Carter, G. (2004). Phase I trial of intramuscular estradiol valerate (I/M-E) in hormone refractory prostate cancer. Journal of Clinical Oncology, 22(14 Suppl) [40th Annual Meeting of the American Society of Clinical Oncology: June 5–8, 2004, Ernest N. Morial Convention Center, New Orleans, Louisiana, Annual Meeting Proceedings], 436–436 (abstract no. 4726). [DOI:10.1200/jco.2004.22.90140.4726] [Google Books] [PDF]
  • Kozlov, G. I., Mel’nichenko, G. A., & Golubeva, I. V. (1985). Sluchai laktorei u bol’nogo muzhskogo pola s transseksualizmom. [Case of galactorrhea in a transsexual male patient.] Problemy Èndokrinologii (Moskva) [Problems of Endocrinology (Moscow)] (in Russian). 31(1), 37–38. [ISSN:0375-9660] [Google Scholar 1] [Google Scholar 2] [PMID:4039061] [DOI:10.14341/probl198531137-38] [PDF] [Translation]
  • Kuhl, H. (1998). Adverse effects of estrogen treatment: natural vs. synthetic estrogens. In Lippert, T. H., Mueck, A. O., & Ginsburg, J. (Eds.). Sex Steroids and the Cardiovascular System: The Proceedings of the 1st Interdisciplinary Workshop, Tuebingen, Germany, October 1996. Parthenon Publishing Group, New York, London (pp. 201–210). London/New York: Parthenon. [Google Scholar] [Google Books] [PDF]
  • Kuhnz, W., Gansau, C., & Mahler, M. (1993). Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol. Arzneimittelforschung, 43(9), 966–973. [Google Scholar] [PubMed] [PDF]
  • Mikkola, A., Ruutu, M., Aro, J., Rannikko, S., & Salo, J. (1999). The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium. Annales Chirurgiae et Gynaecologiae, 88(1), 18–21. [Google Scholar] [PubMed] [PDF]
  • Prior, J. C., Vigna, Y. M., Watson, D., Diewold, P., & Robinow, O. (1986). Spironolactone in the presurgical therapy of male to female transsexuals: Philosophy and experience of the Vancouver Gender Dysphoria Clinic. Journal of Sex Information & Education Council of Canada, 1(1), 1–7. [Google Scholar] [PDF]
  • Sinkula, A. A. (1978). Methods to Achieve Sustained Drug Delivery. The Chemical Approach. In Robinson, J. R. (Ed.). Sustained and Controlled Release Drug Delivery Systems (pp. 411–555). New York/Basel: Marcel Dekker. [Google Scholar] [Google Books] [PDF]
  • Wiemeyer, J. C., Fernandez, M., Moguilevsky, J. A., & Sagasta, C. L. (1986). Pharmacokinetic Studies of Estradiol Enantate in Menopausic Women. Arzneimittel-Forschung, 36(11), 1674–1677. [Google Scholar] [PubMed] [PDF]
  • Wiemeyer, J. C., Fernandez, M., Sagasta, C. L., & Moguilevsky, J. A. (1987). Estudos farmacocinéticos do enantato de estradiol em mulheres na menopausa. [Pharmacokinetic studies of estradiol enantate in menopausic women.] Jornal Brasileiro de Ginecologia, 97(9), 497–501. [Google Scholar] [LILACS] [PDF]
  • Yan, J., Pan, J., Chang, Y., & Kang, J. (1987). The effect of monthly injectable contraceptive megestrol acetate compound on pituitary-ovarian function. 上海第二医科大学学报(英文版) / Journal of Shanghai Second Medical University / Medical Bulletin of Shanghai Jiaotong University, 1(2), 7–12. [Google Scholar] [CNKI] [PDF]
  • …

Paywalled and Not on Sci-Hub or LibGen

  • Baker, V. L. (1994). Alternatives to Oral Estrogen Replacement: Transdermal Patches, Percutaneous Gels, Vaginal Creams and Rings, Implants, and Other Methods of Delivery. Obstetrics and Gynecology Clinics of North America, 21(2) [Primary Care of the Mature Woman], 271–297. [DOI:10.1016/S0889-8545(21)00629-X] [PDF]
  • Chien, Y. W. (1981). Long-acting parenteral drug formulations. Journal of Parenteral Science and Technology / PDA Journal of Pharmaceutical Science and Technology, 35(3), 106–139. [Google Scholar] [URL] [PDF]
  • Sang, G. W., Ge, J. L., Liu, X. H., Shao, Q. X., Zhao, X. J., & Mao, S. M. (1987). 不同剂量庚炔诺酮单独或配伍戊酸雌二醇后的药代动力学及药效学. [Pharmacokinetics and pharmacodynamics of different doses of norethisterone enanthate alone and in combination with estradiol valerate.] 中国 临 床药理 学杂志 / Chinese Journal of Clinical Pharmacology, 3(1), 7–18. [Google Scholar] [CNKI] [DOI:10.13699/j.cnki.1001-6821.1987.01.002] [PDF]
  • Schug, B. S., Donath, F., & Blume, H. H. (2012). Bioavailability and pharmacodynamics of two 10-mg estradiol valerate depot formulations following IM single dose administration in healthy postmenopausal volunteers. International Journal of Clinical Pharmacology and Therapeutics, 50(2), 100–117. [Google Scholar] [DOI:10.5414/cp201589] [PDF 1] [PDF 2]
  • …

Not Readily Accessible Online

  • Bässler, R. (1970). The Morphology of Hormone Induced Structural Changes in the Female Breast. In Altmann, H.-W., et al. (Eds.). Current Topics in Pathology: Ergebnisse der Pathology, Volume 53 (pp. 1–89). Heidelberg: Springer Berlin. [DOI:10.1007/978-3-662-30514-0] [PDF]
  • Basson, R., & Prior, J. C. (1998). Hormonal Therapy of Gender Dysphoria: The Male-to-Female Transsexual. In Denny, D. (Ed.). Concepts in Transgender Identity (Garland Gay and Lesbian Studies, Volume 11) (pp. 277–296). New York: Garland Publishing Inc. [Google Scholar] [Google Books] [PDF]
  • Cooper, M. A. (1984). Hormone treatment clinic for transsexuals. Hawaii Medical Journal, 43(5), 142–144. [Google Scholar] [PubMed] [Archive.org] [PDF]
  • Folley, S. J. (1952). Lactation. In Parkes, A. S. (Ed.). Marshall’s Physiology of Reproduction, Volume II, 3rd Edition. Longmans, Green and Co.: London. [Google Scholar] [Google Books] [PDF]
  • Kloosterboer, H. J., Schoonen, W. G., & Verheul, H. A. (2008). Proliferation of Breast Cells by Steroid Hormones and Their Metabolites. In Pasqualini, J. R. (Ed.). Breast Cancer: Prognosis, Treatment, and Prevention, 2nd Edition (pp. 343–366). New York/London: Informa Healthcare. [Google Scholar] [PDF]
  • Kuhl, H. (1997). Ideal dose of ethinylestradiol. In Elstein, M. (Ed.). Extragenital Effects of Oral Contraceptives: [4th Congress of the European Society of Contraception, Barcelona, Spain, June 1996] (pp. 27–38). Lancashire/New York: Parthenon. [Google Scholar] [Google Books] [Partial PDF]
  • Kuhl, H. (1999). Hormonal contraception. In Oettel, M., & Schillinger, E. (Eds.). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen (Handbook of Experimental Pharmacology, Volume 135, Part 2) (pp. 363–407). Berlin/Heidelberg: Springer. [DOI:10.1007/978-3-642-60107-1_18] [PDF]
  • Kuhl, H. (2005). Gallbladder, liver, pancreas. In Lauritzen, C., & Studd, J. (Eds.). Current Management of the Menopause (pp. 362–372). London/New York: Taylor & Francis. [Google Scholar] [Google Books] [PDF]
  • Laurence, D. J., Monaghan, P., & Gusterson, B. A. (1991). The Development of the Normal Human Breast. Oxford Reviews of Reproductive Biology, 13, 149–174. [Google Scholar] [PubMed] [Archive.org] [PDF]
  • Prior, J. C., & Elliott, S. (1998). Hormonal Therapy of Gender Dysphoria: The Female-to-Male Transsexual. In Denny, D. (Ed.). Concepts in Transgender Identity (Garland Gay and Lesbian Studies, Volume 11) (pp. 297–313). New York: Garland Publishing Inc. [Google Scholar] [Google Books] [PDF]
  • Sahlin, L., & Schoultz, B. V. (1999). Liver Inclusive Protein, Lipid and Carbohydrate Metabolism. In Oettel, M., & Schillinger, E. (Eds.). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen (Handbook of Experimental Pharmacology, Volume 135, Part 2) (pp. 163–178). Berlin/Heidelberg: Springer. [DOI:10.1007/978-3-642-60107-1_8] [PDF]
  • Seal, L. J. (2007). The Practical Management of Hormonal Treatment in Adults with Gender Dysphoria. In Barrett, J. (Ed.). Transsexual and Other Disorders of Gender Identity: A Practical Guide to Management (pp. 157–190). Oxford/New York: Radcliffe Publishing. [Google Scholar] [Google Books] [DOI:10.1201/9781315377605-15] [PDF]
  • …

Translations Only

  • Göretzlehner, G., Ackermann, W., Angelow, K., Bergmann, G., Bieck, E., Golbs, S., & Kliem, O. (2002). Pharmakokinetik von Estron, Estradiol, FSH, LH und Prolaktin nach intramuskulärer Applikation von 5 mg Estradiolvalerat. [Pharmacokinetics of estradiol valerate in postmenopausal women after intramuscular administration.] Journal für Menopause, 9(2), 46–49. [Google Scholar] [URL] [PDF] [Translation]
  • Kaiser, R. (1962). Über die Oestrogenausscheidung nach Injektion von Oestradiolestern. [Estrogen excretion after injection of estradiol esters.] In Nowakowski, H. (Ed.). Gewebs-und Neurohormone: Physiologie des Melanophorenhormons [Tissue and Neurohormones: Physiology of the Melanophore Hormone] (pp. 227–232). Berlin/Heidelberg: Springer. [DOI:10.1007/978-3-642-86860-3_24] [Translation]
  • Kuhl, H. (1990). Ovulationshemmer: Die Bedeutung der Östrogendosis. [Ovulation Preventives: The Significance of the Estrogen Dose. / Ovulation Inhibitors: The Significance of Estrogen Dose.] Geburtshilfe und Frauenheilkunde, 50(12), 910–922. [Google Scholar 1] [Google Scholar 2] [PubMed] [DOI:10.1055/s-2008-1026392] [Translation]
  • Kuhl, H., & Wiegratz, I. (2021). Pharmakokinetik und Pharmakodynamik der in der Assistierten Reproduktion Verwendeten Gestagene. [Pharmacokinetics and Pharmacodynamics of Progestogens Used in Assisted Reproduction.] Gynäkologische Endokrinologie [Gynecological Endocrinology], 19, 105–117. [Google Scholar] [DOI:10.1007/s10304-020-00372-5] [Translation]
  • Premoli, F., Re, I., Asenjo, G., Maximino, G., & Micheletti, L. (2005). Tratamiento del Cáncer de Próstata Avanzado con Estrógenos Transdérmicos Escrotales (ETE). [Transdermal Scrotal Estrogen Patches (TSEP) in the Treatment of Advanced Prostate Cancer.] Revista Argentina de Urología, 70(4), 231–241. [Google Scholar] [URL] [PDF] [Translation]
  • Sapin, R., Neamtu, D., Gasser, F., Ohl, J., Grunenberger, F., & Grucker, D. (2000). De la prudence lors de l’utilisation des dosages directs de progestérone. [Caution when using direct progesterone assays.] Immuno-analyse et Biologie Spécialisée, 3(15), 203–204. [DOI:10.1016/S0923-2532(00)80010-1] [Translation]
  • Valle Alvarez, D. C. (2011). Efecto de una Dosis de 50 mg de Enantato de Noretisterona y 5 mg de Valerato de Estradiol en los Niveles de Testosterona Total en Hombres Mexicanos Sanos. [Effect of a Dose of 50 mg of Norethisterone Enanthate and 5 mg of Estradiol Valerate on Total Testosterone Levels in Healthy Mexican Men.] (Masters thesis, National Polytechnic Institute of Mexico.) [Google Scholar] [URL] [PDF] [Translation]
  • …

PDFs and Translations

  • Becerra Fernández, A., de Luis Román, D. A., & Piédrola Maroto, G. (1999 October 23). Morbilidad en Pacientes Transexuales con Autotratamiento Hormonal para Cambio de Sexo. [Morbidity in Transsexual Patients with Cross-Gender Hormone Self-Treatment.] Medicina Clínica (Barcelona), 113(13), 484–487. [ISSN:0025-7753] [Google Scholar 1] [Google Scholar 2] [PubMed] [WorldCat] [EurekaMag] [PDF 1] [PDF 2] [Translation]
  • Derra, C. (1981). Hormonprofile unter Östrogen- und Antiandrogentherapie bei Patienten mit Prostatakarzinom: Östradiolundecylat versus Cyproteronacetat. [Hormone Profiles under Estrogen and Antiandrogen Therapy in Patients with Prostate Cancer: Estradiol Undecylate versus Cyproterone Acetate.] (Doctoral dissertation, University of Mainz.) [Google Scholar] [WorldCat] [PDF] [Translation]
  • Geppert, G. (1975). Untersuchungen zur Pharmakokinetik von Östradiol-17β, Östradiol-Benzoat, Östradiol-Valerianat und Östradiol-Undezylat bei der Frau: Der Verlauf der Konzentrationen von Östradiol-17β, Östron, LH und FSH im Serum. [Studies on the Pharmacokinetics of Estradiol-17β, Estradiol Benzoate, Estradiol Valerate, and Estradiol Undecylate in Women: The Course of the Relationships Between Estradiol-17β, Estrone, LH, and FSH in Serum.] (Doctoral dissertation, University of Bonn.) [Google Scholar] [WorldCat] [PDF] [Translation]
  • Ghazli, M., Morsad, F., Salah-Eddine, A., El Karroumi, M., Samouh, N., Matar, N., & El Mansouri, A. (2000). La Puberté Féminine: Résultats d’une Enquête auprès de 2000 Adolescentes Marocaines. [Female Puberty: Results of a Survey of 2000 Moroccan Adolescent Girls.] Maghreb Médical, 20(345), 99–104. [Google Scholar] [WHO] [PDF] [Translation]
  • Ittrich, G., & Pots, P. (1965). Östrogenbestimmungen in Blut und Urin nach Verabreichung von Östrogenen. [Estrogen determinations in blood and urine after administration of estrogens.] In Kraatz, H. (Ed.). International Symposium der Gynäkologischen Endokrinologie vom 15. bis 18. Mai 1963. / Abhandlungen der Deutschen Akademie der Wissenschaften zu Berlin, Klasse für Medizin, 1965(1), 53–56. [ISSN:0568-4250] [WorldCat 1] [WorldCat 2] [WorldCat 3] [PDF] [Translation]
  • Kaiser, R. (1961). Die Östrogenausscheidung im Zyklus und nach Injektion von Ostradiolester: Ein Beitrag zur Therapie mit Depotsöstrogenen. [Estrogen excretion during the cycle and after injection of estradiol esters. A contribution to therapy with depot estrogens.] Geburtshilfe und Frauenheilkunde, 21, 868–873. [Google Scholar] [PubMed] [PDF] [Translation]
  • Kuhl, H. (1986). Hormonsubstitution durch Injektionspräparate und Hautimplantate. [Hormone substitution by injectable preparations and skin implants.] Der Gynäkologe, 19(4), 241–247. [Google Scholar] [PubMed] [PDF] [Translation]
  • Lauritzen, C. (1988). Natürliche und synthetische Sexualhormone – Biologische Grundlagen und Behandlungsprinzipien. [Natural and Synthetic Sexual Hormones – Biological Basis and Medical Treatment Principles.] In Lauritzen, C., Schneider, H. P. G., & Nieschlag, E. (Eds.). Grundlagen und Klinik der Menschlichen Fortpflanzung [Foundations and Clinic of Human Reproduction] (pp. 229–306). New York: Walter de Gruyter Berlin. [PDF] [Translation]
  • Leyendecker, G., Geppert, G., Nocke, W., & Ufer, J. (1975). Untersuchungen zur Pharmakokinetik von Östradiol-17β, Östradiol-Benzoat, Östradiol-Valerianat und Östradiol-Undezylat bei der Frau: Der Verlauf der Konzentrationen von Östradiol-17β, Östron, LH und FSH im Serum. [Estradiol-17β, Estrone, LH and FSH in Serum After Administration of Estradiol-17β, Estradiol-Benzoate, Estradiol-Valeriate and Estradiol-Undecylate in the Female.] Geburtshilfe und Frauenheilkunde, 35(5), 370–374. [Google Scholar] [PubMed] [PDF] [Translation]
  • Müderris, İ. İ., & Öner, G. (2009). Hirsutizm Tedavisinde Flutamid ve Bikalutamid Kullanımı. [Flutamide and Bicalutamide Treatment in Hirsutism.] Türkiye Klinikleri Endokrinoloji-Özel Dergisi [Türkiye Klinikleri Endocrinology-Special Topics], 2(2), 110–112. [ISSN:1308-0954] [URL] [PDF] [Translation]
  • Saborowski, K.-J. (1987). Konservative Therapie mit Cyproteronacetat und Estradiolundecylat beim Fortgeschrittenen Prostatacarcinom: Eine 5-Jahres-Studie. [Conservative Therapy with Cyproterone Acetate and Estradiol Undecylate in Advanced Prostate Cancer: A 5-Year Study.] (Doctoral dissertation, Ruhr-University Bochum.) [58 pages] [Google Scholar] [Google Books] [WorldCat] [PDF] [Translation]
  • Varangot, J., & Cedard, L. (1957). Modifications des Œstrogènes Sanguins Après Administration Intramusculaire de Benzoate d’Œstradiol. [Changes in Serum Estrogens After Intramuscular Administration of Estradiol Benzoate.] Comptes Rendus des Séances de la Société de Biologie et de ses Filiales, 151(10), 1707–1712. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF] [Translation]
  • Vizziello, G., D’Amato, G., Trentadue, R., & Fanizza, G. (1993). Studio dinamico del blocco ipofisario indotto dalla triptorelina, mediante test all’estradiolo benzoato. [Estradiol benzoate test in the study of pituitary block induced by triptorelin.] Minerva Ginecologica, 45(4), 185–189. [Google Scholar] [PubMed] [PDF] [Translation]
  • …